Navigation Links
Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009
Date:8/6/2009

atents owned or controlled by third parties; our ability to obtain rights to technology from licensors; liability for patent claims and other claims asserted against us; our ability to obtain and enforce timely patent and other intellectual property protection for our technology and products; the ability to enter into, and to maintain, corporate alliances relating to the development and commercialization of our technology and products; market acceptance of our technology and products; our ability to successfully manufacture, market and sell our products; the availability of capital to finance our activities; our ability to restructure and to service our debt obligations; and any other factors referenced in our other filings with the applicable Canadian securities regulatory authorities or the Securities and Exchange Commission ("SEC"). For a more thorough discussion of the risks associated with our business, see the "Risk Factors" section in our annual report for the year ended December 31, 2008 filed with the SEC on Form 10-K, and our quarterly report for the three months ended March 31, 2009 filed with the SEC on Form 10-Q.

Given these uncertainties, assumptions and risk factors, investors are cautioned not to place undue reliance on such forward-looking statements. Except as required by law, we disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained in this presentation to reflect future results, events or developments.

(C)2009 Angiotech Pharmaceuticals, Inc. All Rights Reserved.

About Angiotech Pharmaceuticals

Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company with over 1,500 dedicated employees. Angiotech discovers, develops and markets innovative treatment solutions for diseases or complications associated with medical device implants, surgical interventions and acute in
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related biology technology :

1. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
4. Angiotech to participate in UBS Global Life Sciences Conference
5. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Angiotech to participate in Bank of America 2007 Credit Conference
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
11. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... Senior Vice President, General Manager ... skills, business acumen Elsevier , a ... and services, congratulates Diane Bartoli , Senior Vice ... Elsevier Clinical Solutions, for being recognized in the 13 ... issue of Profiles in Diversity Journal ® ...
(Date:11/22/2014)... Boston, MA (PRWEB) November 21, 2014 ... and key investors will gather on December 3rd ... Boston Biotech Conferences series. GeneticRx will take place ... Harvard Medical School and will discuss the present ... gene therapy, exon skipping, and gene editing—as well ...
(Date:11/22/2014)... (PRWEB) November 22, 2014 The ... Analytical, Preparative), by Material (Metal, Glass, Plastic), by ... TLC, SFC] - Forecast to 2018” analyses and ... challenges in North America, Europe, Asia, and Rest ... tables and 15 figures spread through 135 pages ...
(Date:11/21/2014)... LAVAL, Quebec , November 21, 2014 ... KLOX como responsable comercial   Mariano Rodríguez ... finanzas   KLOX está en marcha para ... tratamiento de cura de heridas de reciente aprobación en Europa ... o "la compañía") se complace al anunciar los siguientes nombramientos: ...
Breaking Biology Technology:Elsevier Clinical Solutions' Diane Bartoli Featured In Profiles in Diversity Journal's 13th Annual Women Worth Watching Issue 2Elsevier Clinical Solutions' Diane Bartoli Featured In Profiles in Diversity Journal's 13th Annual Women Worth Watching Issue 3Pioneering Academics and Key Industry Leaders to Discuss Rare Diseases and the Emergence of New Genetic Medicines at Genetic Rx on December 3rd 2Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 2Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 3Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 4Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 5KLOX Technologies anuncia sus nombramientos ejecutivos 2KLOX Technologies anuncia sus nombramientos ejecutivos 3KLOX Technologies anuncia sus nombramientos ejecutivos 4KLOX Technologies anuncia sus nombramientos ejecutivos 5
... match charitable corporate donations with organizations that need them, ... and CEO. , ,The non-profit was begun in 2000 ... a supply-chain software provider. Since then it has crafted ... humanitarian groups. In 2001 Aidmatrix worked with an international ...
... Memorial High in Madison, Wisconsin, won a $20,000 scholarship for ... applications. , ,She took 10th place in the Intel Science ... groups in finite groups." The awards were handed out in ... ,Top prize of $100,000 went to a New York student ...
... As a former attorney and current managing director of ... has tackled his share of challenges. But the tasks ... Public Advisory Committee, for which he recently began serving ... , ,"I have to tell you, it's a very ...
Cached Biology Technology:Online aid group taps former Wisconsin governor McCallum 2Online aid group taps former Wisconsin governor McCallum 3Gulbrandsen tackles 'daunting' challenges in Patent Office 2
(Date:11/7/2014)... 2014  In conjunction with the Glendale ... Community Foundation of the Verdugos has announced the " ... a $250,000 initiative to keep the Verdugo Regional Crime Lab ... six months of existence, the Lab has processed more than ... law enforcement. "Because our number one priority is ...
(Date:11/6/2014)... MD, November 6, 2014 - Insilico Medicine, Inc, ... aging and age related diseases announced a research ... of cancer, Champions Oncology, Inc (OTC: CSBR). , ... for personalized medicine, but Champions Oncology,s TumorGraft technology ... validate the chemotherapy regimen experimentally generating vast amounts ...
(Date:11/4/2014)... amount of death at the right time might actually ... research that could help in understanding animal populations, pest ... a paper in the journal Trends in Ecology ... colleagues conclude that the kind of positive population effect ... or mortality, depends on the size and developmental stage ...
Breaking Biology News(10 mins):Community Foundation Of The Verdugos Unveils Campaign To Fund Glendale-Burbank DNA Justice Project 2Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2When less is more: Death in moderation boosts population density in nature 2
... proteins and other chemicals that underlies most biological ... that accelerate chemical reactions between molecules. The creation ... synthesis of chemicals and pharmaceuticals, devise new tools ... In the August 16 issue of Nature, ...
... reported in the August issue of Cell Stem Cell, a ... the HIV/AIDS virus leads to learning and memory deficits, a ... surface of the virus not only kills some mature brain ... the birth of new brain cells by crippling adult neural ...
... A mysterious epidemic of thyroid disease among pet ... exposure to dust shed from flame retardants in household ... in a study scheduled for publication the Aug. 15 ... journal from the American Chemical Society, the worlds largest ...
Cached Biology News:MGH researchers describe new way to identify, evolve novel enzymes 2HIV is a 'double hit' to the brain 2Study links cat disease to flame retardants in furniture and to pet food 2Study links cat disease to flame retardants in furniture and to pet food 3
Mouse monoclonal antibody raised against a full length recombinant SCGB3A2. NCBI Entrez Gene ID = SCGB3A2...
Mouse monoclonal antibody raised against a partial recombinant QARS. NCBI Entrez Gene ID = QARS...
Mouse polyclonal antibody raised against a partial recombinant QPCT. NCBI Entrez Gene ID = 25797...
Mouse monoclonal antibody raised against a partial recombinant QPCT. NCBI Entrez Gene ID = QPCT...
Biology Products: